Bradley Pharmaceuticals Overview
- Founded
-
1985
- Status
-
Acquired/Merged
- Employees
-
300
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
3
Bradley Pharmaceuticals General Information
Description
Operator of a specialty pharmaceutical company. The company markets to niche physician specialties in the U.S. and international markets. The company commercializes brands, develops new products through lifecycle management and in-licenses phase II and phase III drugs with long-term intellectual property protection. It specializes in pharmaceuticals for dermatology, podiatry, gastroenterology, women's health, respiratory and internal medicine products.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 383 Route 46 West
- Fairfield, NJ 07004
- United States
Bradley Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bradley Pharmaceuticals Patents
Bradley Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040156874-A1 | Can be applied to the affected dermal site formulated as a cream, lotion, solution, gel, lacquer, ointment, foam, or any vehicle capable of applying urea directly to the affected site. | Abandoned | 11-Feb-2003 | 00000000 | 0 |
| US-20040156870-A1 | Administering urea to the affected area of human skin either before, after or with a topical anti-inflammatory drug. | Abandoned | 11-Feb-2003 | 000000000 | 00 |
| US-20040127512-A1 | Administering methscopolamine bromide for therapy of symptoms of non-constipated irritable bowel syndrome (ibs) and diarrhea-predominant ibs | Abandoned | 30-Dec-2002 | 00000000000 | 0 |
| US-20040018221-A1 | A mixture of urea and vitamin e for treating dry skin, dermatitis, eczema, debridement; cosmetics, skin disorders | Abandoned | 28-Nov-2001 | 0000000000 | 0 |
| US-20030138466-A1 | Topical products with antioxidant formulations to prevent uv-induced carcinogenesis and photoaging and to modulate desquamatory skin disorders; comprising 40 wt-% urea, 0.1-20 wt-% antioxidant, balance excipients | Abandoned | 28-Nov-2001 | A61Q19/007 | 00 |
Bradley Pharmaceuticals Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Daniel Glassman | President & Chief Executive Officer & Founder | ||
| Brent Lenczycki | Chief Financial Officer & Vice President |
Bradley Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
